TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03219164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
Study: NCT01005160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: CKD-501 0.5mg, metformin 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, metformin 1000mg
Study: NCT01608425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine consultations
Description: Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
Study: NCT00500266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Study: NCT04607395

Intervention type: RADIATION
Intervention: pre-operative radiograph
Description: Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio).
Study: NCT01431287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose or high dose
Study: NCT02556164

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Body-worn sensor technology
Description: Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
Study: NCT00938886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Daily 50 mg naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched naltrexone placebo
Study: NCT01431287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose or high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT00136864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Diagnostic Imaging
Description: Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
Study: NCT01775748

Intervention type: OTHER
Group type: OTHER
Intervention: Active Concord Grape Juice 12 oz per day
Description: Grape Juice 12 oz per day

Intervention type: OTHER
Group type: OTHER
Intervention: Active Concord Grape Juice 12 oz per day
Description: Grape Juice 12 oz per day

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Grape Juice 12 oz per day
Description: Placebo Grape Juice 12 oz per day

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Grape Juice 12 oz per day
Description: Placebo Grape Juice 12 oz per day
Study: NCT03733912

Intervention type: OTHER
Intervention: Phthalate metabolites measurement
Description: To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups

Intervention type: OTHER
Intervention: Phthalate metabolites measurement
Description: To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
Study: NCT03089788

Intervention type: OTHER
Group type: OTHER
Intervention: Home-based test
Description: Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.

Intervention type: OTHER
Group type: OTHER
Intervention: Skin test
Description: Skin Prick Tests will be performed with registered cat allergen extract.
Study: NCT01622426

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tolerance to a new aminoacid based formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tolerance to a new aminoacid based formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
Study: NCT02967757

Intervention type: DRUG
Intervention: liraglutide
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
Study: NCT02420834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypromellose 0.15%
Description: Tear supplement to be taken as required to relieve symptoms
Study: NCT03055026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Tablets
Study: NCT02420834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypromellose 0.4%
Description: Tear supplement to be taken as required to relieve symptoms
Study: NCT04825353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic compbined guided PCNL
Description: patient undergo stone removal by ECIRS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCNL
Description: patient undergo SPCNL
Study: NCT03055026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT03148730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop group
Description: Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
Study: NCT02285179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
Study: NCT00222716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving counseling
Description: Telephone nurse counseling behavioral intervention focused on problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving counseling
Description: Telephone nurse counseling behavioral intervention focused on problem solving.
Study: NCT00300430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and rosuvastatin calcium
Description: ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and atorvastatin calcium
Description: ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and simvastatin
Description: ABT-335 135 mg plus simvastatin daily, 52 weeks
Study: NCT03415386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet drugs and anticoagulants for at least one month
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet drugs and anticoagulants for at least one month
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet drugs and anticoagulants for at least one month
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet drugs and anticoagulants for at least one month
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
Study: NCT02325843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human bone marrow MSC
Description: The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
Study: NCT01517971

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01715129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate 11.25mg
Study: NCT02285179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: daily dose of 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: daily dose of 20 mg
Study: NCT03677193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing ICP game
Description: Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
Study: NCT02452333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncoplastic Approach Excisional Breast Biopsy
Description: Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Excisional Breast Biopsy
Description: Conventional Excisional Breast Biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tezel Method of Breast Volume Measurement
Description: Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tezel Method of Breast Volume Measurement
Description: Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Assessment
Description: Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Assessment
Description: Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
Study: NCT03069651

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Care
Description: The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Care
Description: The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
Study: NCT03900195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BottlePEP
Description: Positive expiratory device with a bottle
Study: NCT04824378

Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.Only learn ICG image features of different label groups

Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.Only learn ICG image features of different label groups

Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.Only learn ICG image features of different label groups
Study: NCT00239031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium
Description: Enteric-Coated Mycophenolate Sodium
Study: NCT02087332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged release Torasemide (Britomar)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torasemide (Diuver)
Study: NCT02151513

Intervention type: DEVICE
Intervention: Intrathecal Pump Placement
Study: NCT01746251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Study: NCT05895916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-volume road cycling
Description: 1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
Study: NCT01615497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment as Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
Study: NCT01549301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: filgrastim, single dose, s.c., dosage: 5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: filgrastim, single dose, s.c., dosage: 10 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim, i.v., single dose, dosage: 5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim, i.v., single dose, dosage: 10 mcg/kg
Study: NCT04256967

Intervention type: OTHER
Intervention: Body and health focused study environment
Description: Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
Study: NCT00624221

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Descemet's stripping endothelial keratoplasty
Description: Small incision corneal transplant procedure to treat dysfunctional endothelium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Descemet's stripping endothelial keratoplasty
Description: Small incision corneal transplant procedure to treat dysfunctional endothelium.
Study: NCT03592459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macy Catheter
Description: Undergo placement of Macy catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Receive opioids via Macy catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00127127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
Study: NCT00935883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
Study: NCT03396328

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional low salt education
Description: conventional low salt education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive low salt dietary education by smartphone application
Description: Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
Study: NCT01974817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent conjugate pneumococcal vaccine
Description: 0.5ml IM for one dose
Study: NCT03195894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TripleA
Study: NCT03593915

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Description: PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine.